COVID-19 Vaccination Efficacy in Previously Infected Individuals: New Research Offers Insights

Strategic Insights -

Researchers at Boston University have published a study examining the effectiveness of COVID-19 vaccinations in individuals with a history of SARS-CoV-2 infection. The study aimed to clarify the durability of anti-viral antibody responses, which is crucial for epidemiological applications. The investigators utilized the BU ELISA protocol to measure circulating SARS-CoV-2 receptor-binding domain (RBD) and nucleocapsid (N) specific IgG and IgA antibody levels in a cohort of individuals infected with SARS-CoV-2 in the spring of 2020. The results showed that vaccine-induced antibody responses in individuals previously infected with SARS-CoV-2 were elevated and sustained for more than one year post-vaccination.

Key Takeaways:

  • The study found that individuals infected with SARS-CoV-2 prior to COVID-19 vaccination maintained vaccine-induced RBD-specific antibody levels and viral neutralization activity for one year.
  • Vaccine-induced antibody responses in previously infected individuals were elevated and sustained for more than one year post-vaccination.
  • Neutralization activity against WA-1, Delta, and Omicron increased and remained higher than pre-vaccination levels for one year after the first COVID-19 vaccine dose.
  • The study suggests that an annual booster would stably boost anti-SARS-CoV-2 antibody responses, preventing infection and disease.
  • The researchers used the BU ELISA protocol to measure circulating SARS-CoV-2 RBD and N specific IgG and IgA antibody levels in a cohort of individuals infected with SARS-CoV-2 in the spring of 2020.
  • The study included a sample collection spanning six months to two years post-symptom onset and interrogated neutralization activity against the ancestral SARS-CoV-2 (WA-1) and Delta and Omicron (BA.1) variants.
  • The findings indicate that infection followed by vaccination yields robust antibody responses against SARS-CoV-2 that endure for one year.

Statistics:

  • The study included a sample collection spanning six months to two years post-symptom onset.
  • The results showed that vaccine-induced antibody responses in previously infected individuals were elevated and sustained for more than one year post-vaccination.
  • Neutralization activity against WA-1, Delta, and Omicron increased and remained higher than pre-vaccination levels for one year after the first COVID-19 vaccine dose.

Sources:

  • Individuals Infected with SARS-CoV-2 Prior to COVID-19 Vaccination Maintain Vaccine-Induced RBD-Specific Antibody Levels and Viral Neutralization Activity for One Year. Viruses, 2025,17(5):640.
  • Viruses - http://www.mdpi.com/journal/viruses
  • The publisher for Viruses is MDPI AG.